Cyclic ester or amide derivatives

Patent Citations (91)

Non-Patent Literature (122)

• Ando, Takao et al., “Formation of Crossed Phenzine from the Reaction between Tetra-p-anisyl- and Tetra-p-tolyl-hydrazines in Liquid Sulphur Dioxide,” Chem. Comm., S. Chem. Comm., 1975, 989.Applicant
• Andrus, Merrit B., “Structure-based design of an acyclic ligand that bridges FKBP12 and calcineurin,” J. Am. Chem. Soc., 1993, 115(2), 10420-1.Applicant
• Armistead, D.M. et al., “Design, synthesis and structure of non-macrocyclic inhibitors of FKBP12, the major binding protin for the immunosuppressant FK506,” Acta Crystallogr. 1995, D51(4), 522-8.Applicant
• Askin, D. et al., “Chemistry of FK-506: benzilic acid rearrangement of the tricarbonyl system,” Tetrahedron Lett., 1989, 30(6), 671-4.Applicant
• Askin, D. et al., “Effecient Degradation of FK-506 to a versatile synthetic intermediate,” J. Org. Chem., 1990, 55(20), 5451-4.Applicant
• Baader, Ekkehard et al., “Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues,” Biochem. J., 1994, 300(2), 525-30.Applicant
• Baumann, K. et al., “Synthesis and oxidative cleavage of the major equilibrium products of ascomycin and Fk 506,” Tetrahedron Lett., 1995, 26(13), 2231-4.Applicant
• Bender, D., et al., “Periodate oxidation of α-keto γ-lactams. Enol oxidation and β-lactam formation. Mechanism of periodate hydroxylation reactions,” J. Org. Chem., 1978, 43(17), 3354-62.Applicant
• Birkenshaw, T.N. et al., “Synthetic FKBP12 Ligands. Design and Synthesis of Pyranose Replacements,” Bioorganic & Medicinal Chemistry Letters, (1994) 4:21, 2501-2506.Applicant
• Boulmedais, Ali et al., “Stereochemistry of Electrochemical Reduction of Optically Active α-ketoamides. II. Electroreduction of benzoylformamides derived from S-(-)-proline,” Bull. Soc. Chim. Fr., 1989, (2), 185-91. (French).Applicant
• Cameron, Andrew et al., “Immunophilin FK506 binding protein associated with inositol 1,4,5-triphosphate receptor modulates calcium flux,” Proc. Natl. Acad. Sci. USA, 1995, 92, 1784-1788.Applicant
• Caufield, Craig E. and Musser, John H., “Macrocyclic Immunomodulators,” Annual Reports in Medicinal Chemistry, Johns (Ed.), Academic Press, Chapter 21, 195-204, 1989.Applicant
• Caffrey, M.V. et al., “Synthesis and Evaluation of Dual Domain Macrocyclic FKBP12 Ligands,” Bioorganic & Medicinal Chemistry Letters, (1994) 4:21, 2507-2510.Applicant
• Chakraborty, TK et al., “Design and Synthesis of a rampamycin-based high affinity binding FKBP12 ligand,” Chem. Biol., 1995, 2(3), 157-61.Applicant
• Chakaraborty, Tushar K., “Studies towards the development of cyclic peptide-based analogs of macrolide immunosuppressants,” Pure Appl. Chem., 1996, 68(3), 565-568.Applicant
• Coleman, R., and Danishefsky, S., “Degradation and manipulations of the immunsuppressant FK506: preparation of potential synthetic intermediates” Heterocycles, 1989, 28(1), 157-61.Applicant
• Colombo, L. et al., “Enantioselective synthesis of secondary alcohols in the presence of chiral ligands,” Tetrahedron, 1982, 38(17), 2725-7.Applicant
• Cunliffe, C. Jane et al., “Novel inhibitors of prolyl 4-hydroxylase. 3. Inhibition by the substrate analog N-oxaloglycine and its derivatives,” J. Med. Chem., 1992, 35 (14), 2652-8.Applicant
• Cushman, D.W. et al., “Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoly and mercaptoalkanoyl amino acids,” Biochemistry, 1977, 16(25), 5484-91.Applicant
• Dawson, Ted M. et al., “Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity,” Proc. Natl. Acad. Sci. USA, 1993, 90, 9808-12.Applicant
• Dawson, T.M. et al., “The immunophilins, FK506 binding and cyclophilin, are discretely localized in the brain: relationship to calcineurin,” Neuroscience, 1994, 62(2), 569-80.Applicant
• Effenberger F. et al., “Diastereoselective addition of benzenesulfenyl chloride to 1-acryloylproline esters,” Chemical Abstracts, 1989, 110:154846h.Applicant
• Egbertson, M. and Danishefsky, S., “A synthetic route to the tricarbonyl region of FK-506,” J. Org. Chem., 1989, 54(1), 11-12.Applicant
• Feutren, Gilles, “The Optimal use of Cyclosporin A in Autoimmune Diseases,” J. of Autoimmunity, 1992, 5, 183-95.Applicant
• Finberg, Robert W. et al., “Prevention of HIV-1 Infection and Preservation of CD4 Function by the binding of CPFs to gp120,” Science, 1990, 249, 287-91.Applicant
• Fisher, Matthew et al., “On the remarkable propensity for carbon-carbon bond cleavage reactions in teh C(8)-C(10) region of FK-506,” J. Org. Chem., 1991, 56(8), 2900-7.Applicant
• Fry, Lionel, “Psoriasis: Immunopathology and Long-term treatment with Cyclosporin,” J. of Autoimmunity, 1992, 5, 277-83.Applicant
• Furber, Mark, “FKBP-12-ligand-calceineurin interactions: analogs of SBL506,” J. Am. Chem. Soc., 1995, 117(27), 7267-8.Applicant
• Furber, M. et al., “Studies relating to the immunosuppressive activitiy of FK506,” Tetrahedron Lett., 1993, 34(8), 1351-4.Applicant
• Goodfellow, Val S. et al., “p-Nitrophenyl 3-diazopyruvate and diazopyruvamides, a New Family of Photoactivatable Cross-Linking Bioprobes,” Biochemistry, 28(15), 6346-60.Applicant
• Goulet, Mark T., and Boger, Joshua, “Degradative studies on the tricarbonyl containing macrolide rapamycin,” Tetrahedron Lett., 1990, 31(34), 4845-8.Applicant
• Goulet, Mark T. and Boger, Joshua, “Degradative studies on the tricarbonyl containing macrolide rapamycin,” Tetrahedron Lett., 1991, 32(45), 6454.Applicant
• Haeusler, Johannes and Schmidt, Ulrich, “Amino acids and peptides. IX. Pyruv oyl amino acids,” Chem. Ber., 1974, 107(1), 145-51. (German).Applicant
• Harding, M.W., et al., “A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase,” Nature Lett., 1989, 341, 758-60.Applicant
• Hauske, J.R. et al. “Design and Synthesis of Novel FKBP Inhibitors,” J. of Medicinal Chemistry, (1992) 35, 4284-4296.Applicant
• Hauske, James R. et al., “Investigation of the effects of synthetic, non-cytotoxic immunophilin inhibitors on MDR,” Bioorg. Med. Chem.. Lett., 1994, 4(17), 2097-102.Applicant
• Hayward, C.M. et al., “Total Synthesis of rapamycin via a novel titanium-mediated aldol macrocyclization reaction,” J. Am. Chem. Soc., 1993, 115(20), 9345-6.Applicant
• Hayward, C.M. et al., “An application of the Suarez reaction to the regiospecific synthesis of the C28-C42 segment of rapamycin,” 3989-92.Applicant
• Holt, D.A. et al., “Design, Synthesis, and Kinetic Evaluation of High-Affinity FKBP Ligands and the X-ray Crystal Structures of Their Complexes with FKBP12,” J. Am. Chem. Soc., (1993) 115, 9925-9938.Applicant
• Holt, D.A. et al., “Structure-Activity Studies of Nonmacrocyclic Rapamycin Derivatives,” Bioorganic & Medicinal Chemistry Letters, (1993) 3:10, 1977-1980.Applicant
• Holt, D.A. et al., “Structure-Activity Studies of Synthetic FKBP Ligands as Peptidyl-prolyl Isomers Inhibitors,” Bioorganic & Medicinal Chemistry Letters, (1994) 4:2, 315-320.Applicant
• Hearn, Walter R., and Worthington, Robert E., “L-Proline-N-oxalic anhydride,” J. Org. Chem., 1967, 32(12), 4072-4.Applicant
• Iwabuchi, T. et al., “Effects of immunosuppressive peptidyl-prolyl cis-trans isomerase (PPIase inhibitors, cyclosporin A, FK506, ascomycin and rapamycin, on hair growth initiation in mouse: immunosuppression is not required for hair growth,” J. of Deramatol. Sci., (1995) 9:1, 64-69.Applicant
• Jiang, H. et al., “Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant,” J. Ivest. Dermatol., (1995) 104:4, 523-525.Applicant
• Jones, T. et al., “Chemistry of tricarbonyl hemiketals and application of Evans technology to the total synthesis of the immunosuppressant (-)-FK-506,” J. Am. Chem. Soc., 1990, 112(8), 2998-3017.Applicant
• Jones, A. et al., “A formal synthesis of FK-506. Exploration of some alternatives to macrolactamization,” J. Org. Chem., 1990, 55(9), 2786-97.Applicant
• Kaczmar, et al., Makromol. Chem., 1976, 177, 1981-9 (German).Applicant
• Karle, Isabella L. et al., “Conformation of the oxalamide group in retro-bispeptides. Three crystal structures,” Int. J. Pept. Protein Res., 1994, 43(2), 160-5.Applicant
• Kino, Toru et al., “FK-506, A novel immunosuppressnt isolateded from A streptomyces,” J. of Antibiotics, 1987, 40(9), 1249-55.Applicant
• Kocienski, P. et al., “A synthesis of the C(1)-C(15) segment of tsukubaenolide (FK506),” Tetrahedron Lett., 1988, 29(35), 4481-4.Applicant
• Krit, N.A. et al., “Impact of the nature of alkyl radical on the biological activity of N-carboxyalkyl dipeptides,” Khim.-Farm. Zh., 1991, 25(7), 44-6. (Russian).Applicant
• Linde, Robert G. et al., “Straightforward synthesis of 1,2,3-tricarbonyl systems,” J. Org. Chem., 1991, 56(7), 2534-8.Applicant
• Luengo, Juan I. et al., “Efficient removal of pipecolinate from rapamycin and FK506 by reaction with tetrabutylammonium cyanide,” Tetrahedron Lett., 1993, 34(29), 4599-602.Applicant
• Luengo, J. et al., “Structure-activity studies of rapamycin analogs: evidence that the C-7 methodoxy group is part of the effector domain and positioned at the FKBP:12-FRAP interface,” Chem. Biol., 1995, 2(7), 471-81.Applicant
• Lyons, W. Ernest et al., “Neronal regeneration Enhances the Expression of the Immunophilin FKBP-12,” The Journal of Neuroscience, 1995, 15, 2985-94.Applicant
• Marshall, J.A. et al., Convenient synthesis of dioxopiperazines via aminolysis of .alpha.-(pyruvylamino) esters, Synth. Commun., 1975, 5(3), 237-44.Applicant
• Mashkovskii, M.D. et al., “1-[4-(2-Hydroxy-3-tert-butylaminopropoxy)-indole-3-yl (5-acetamido-1-(S)-carboxypentyl)-DL-alanyl]-L-proline dihydrochloride, a new angiotensin-converting enzyme inhibitor with β-adrenoblocking properties,” Khim.-Farm. Zh., 1993, 27(10), 16-20. (Russian).Applicant
• Munegumi, Toratane et al., “Asymmetric Catalytic Hydrogenations of N-pyruvoyl-(S)-proline esters,” Bull. Chem. Soc. Jpn., 1987, 60(1), 243-53.Applicant
• Munoz, Benito et al., “α-Ketoamide Phe-Pro isostere as a new core structure for the inhibition of HIV protease,” Bioorg. Med. Chem., 1994, 2(10), 1085-90.Applicant
• Nakatsuka, M et al. “Total Synthesis of FK506 and an FKBP Reagent, (C8, C9- 13C2)-FK-506,” J. Am. Chem. Soc., 1990, 112 (14), 5583-90..Applicant
• Nelson, F. et al., “A novel ring contraction of rapamycin,” Tetrahedron Lett., 1994, 35(41), 7557-60.Applicant
• Nicolaou, K.C. et al., “Total Synthesis of rapamycin,” J. Am. Chem. Soc., 1993, 115(10), 4419-20.Applicant
• Pattenden, Gerald and Tankard, Mark, “Facile Synthesis of the tricarbonyl subunit in the immunosuppressant rapamycin,” Tetrahedron Lett., 1993, 34(16), 2677-80.Applicant
• Ponticelli, Claudio, “Treatment of the Nephrotic Syndrome with Cyclosporin A,” J. of Autoimmunity, 1992, 5, 315-24.Applicant
• Ranganathan, Darshan et al., “Protein Backbone Modification by Novel Cα-C Side-Chain Scission,” 1994, J. Am. Chem. Soc., 116(15), 6545-57.Applicant
• Rao, A.V., et al., “Studies directed towards the synthesis of immunosuppressive agent FK-506: construction of the tricarbonyl moiety,” Tetrahedron Lett., 1990, 31(10), 1439-42.Applicant
• Rao, A.V. Rama et al., “Studies directed towards the synthesis of immunosuppressive agent FK-506: synthesis of the entire bottom half,” Tetrahedron Lett., 1991, 32(9), 1251-4.Applicant
• Rao, A.V. Rama and Desibhatla, Vidyanand, “Studies directed towards the syntesis of rapamycin: stereoselective synthesis of C-1 to C-15 segment,”Tetrahedron Lett., 1993, 34(44), 7111-14.Applicant
• Shu, A. et al., “Synthesis of I-125 labeled photoaffinity rapamycin analogs,” J. Labelled Compd. Radiopharm., 1996, 38(3), 277-37.Applicant
• Skotnicki, Jerauld et al., “Ring expanded rapamycin derivatives,” Tetrahedron Lett., 1994, 35(2), 201-2.Applicant
• Skotnicki, Jerauld et al., “Synthesis of secorapamycin esters and amides,” Tetrah. Lett., 1994, 35(2), 197-200.Applicant
• Slee, Deborah H. et al., Selectivity in the Inhibition of HIV and FIV Protease: Inhibitory and Mechanistic Studies of Pyrrolidine-Containing α-Keto Amide and Hydroxyethylamine Core Structures, J. Am. Chem. Soc., 1995, 117(48), 1187-78.Applicant
• Smith, A.B. et al., “Total synthesis of rapamycin and demethoxyrapamycin,” J. Am. Chem. Soc., 1995, 117 (19), 5407-8.Applicant
• Soai, Kenso and Ishizaki, Miyuki, “Diastereoselective asymmetric allylation of chiral α-keto amides with allyltrimethylsilane. Preparation of protected homoallylic alcohols,” J. Chem. Soc., 1984, 15, 1016-1017.Applicant
• Soai, Kenso et al., “Asymmetric Allylation of α-keto amides Derived from (S)-proline esters,” Pept. Chem., 1986, 24, 327-330.Applicant
• Soai, Kenso and Ishizaki, Miyuki, “Asymmetric Synthesis of Functionalized tertiary alcohols by diastereoselective allylation of chiral α-keto amides derived from (S)-proline esters: control of stereochemistry based on saturated coordination of Lewis acid,” J. Org. Chem., 1986, 57(17) 3290-5. (English).Applicant
• Soai, Kenso et al., “Asymmetric synthesis of both eaniomers of α-hydroxy acids by the diastereoselective reduction of chiral α-keto amides with complex metal hydrides in the presence of a metal salt,” Chem. Lett., 1986, 11, 1897-900.Applicant
• Steffan, Robert J. et al., “Base catalyzed degradations of rapamycin,” Tetrahedron Lett., 1993, 34(23), 3699-702.Applicant
• Steglich, Wolfgang et al., “Activated carboxylic acid derivatives. II. A simple synthesis of 2-oxycarboxylic acid amides, N-(2-oxoacyl)amino acid esters and 2-oxocarboxylic acid hydrazides,” Synthesis, 1978, 8, 622-4. (German).Applicant
• Steiner, Joseph P. et al., “High brain densities of the immunophilin FKBP colocalized with calcineurin,” Nature Lett., 1992, 358, 584-7.Applicant
• Steiner, J.P. et al., “Nonimmunosuppressive Ligands for Neuroimmunophilins Promote Nerve Extension In Vitro and In Vivo,” Society for Neuroscience Abstracts, 1996, 22, 297.13.Applicant
• Stocks, M. et al., “The contribution to the binding of the pyranoside sustituents in the excised binding domain of FK-506,” Bioorg. Med. Chem. Lett., 1994, 4(12), 1457-60.Applicant
• Stocks, M. et al., “Macrocyclic ring closures employing the intramolecular Heck reaction,” Tetrahedron Lett., 1995, 36(36), 6555-8.Applicant
• Tanaka, H. et al., “Structure of FK506, a novel imunosuppressant isolated from Streptomyces,” J. Am. Chem. Soc., 1987, 109(16), 5031-3.Applicant
• Tatlock, J. et al., “High affinity FKBP-12 ligands from (R)-(-)-carvone. Synthesis and evaluation of FK506 pyranose ring replacements,” Bioorg. Med. Chem. Lett., 1995, 5(21), 2489-94.Applicant
• Teague, S.J. et al., “Synthesis and Study of a Non-Macrocyclic FK506 Derivative,” Bioorg. Med. Chem. Lett., (1994) 4:13, 1581-1584.Applicant
• Teague, S. et al., “Synthesis of FK506-cyclosporin hybrid macrocycles,” Bioorg. Med. Chem. Lett., 1995, 5(20), 2341-6.Applicant
• Tindall, Richard S.A., “Immunointervention with Cyclosporin A in utoimmune Neurological Disorders,” J. of Autoimmunity, 1992, 5, 301-13.Applicant
• Tugwell, Peter, “Cyclosporin in the Treatment of Rheumatoid Arthritis,” J. of Autoimmunity, 1992, 5, 231-40.Applicant
• Waldmann, Herbert, “Proline benzyl ester as chiral auxilary in Barbier-type reactions in aqueous solution,” 1990, Synlett, 10, 627-8.Applicant
• Wang, C.P. et al., “High performance liquid chromatographic isolation and spectroscopic characterization of three major metabolites from the plasma of rats receiving rapamycin (sirolimus) orally,” J. Liq. Chromatogr., 1995, 18(13), 2559-68.Applicant
• Wang, C.P. et al., “A high performance liquid chromatographic method for the determination of rapamycin {sirolimus} in rat serum, plasma, and blood and in monkey serum,” J. Liq. Chromatogr., 1995, 18(9), 1801-8.Applicant
• Wang, G.T. et al., Synthesis and FKBP Binding of Small Molecule Mimics of the Tricarbonyl Region of FK506, Bioorg. Med. Chem. Lett., (1994) 4:9, 1161-1166.Applicant
• Wasserman, H.H. et al., “Synthesis of the tricarbonyl region of FK-506 through and amidophosphorane [Erratum to document cited in CA111(7):57366p],” J. Org. Chem., 1989, 54(22), 5406.Applicant
• Whitesell, J.K. et al., “Asymmetric Induction. Reduction, Nucleophilic Addition to, Ene Reactions of Chiral α-Ketoesters,” J. Chem. Soc., Chem Commun., 1983, 802.Applicant
• Williams, D.R. and Benbow, J.W., “Synthesis of the α,β diketo amide segment of the novel immunosuppressive FK506,” J. Org. Chem., 1988, 53(191), 4643-4.Applicant
• Yohannes, Daniel et al., “Degradation of rapamycin: synthesis of a rapamycin-derived fragment containing the tricarbonyl and triene sectors,” Tetrahedron Lett., 1993, 34(13), 2075-8.Applicant
• Yamamoto, S. et al., “Stimulation of hair growth by topical application of DK506, a potent immunosuppressive agent,” J. Invest. Dermatol, (1994) 102:2, 160-164.Applicant
• Zaparucha et al., “Asymmetric Synthesis of 3-alkyl pipecolic acids”, Tetrahedron Lett. vol. 40, No. 9, 1999 pp. 3699-3700. (CAS 1999:296090).Applicant
• Asaoka et al., “Chelation controlled cis-selective acylation of 2-(alkoxycarbonyl)cyclopentylzinc iodides”, J. Chem. Soc., Perkin Trans. 1 vol. 20, 1997 pp. 2949-2950. (CAS 1997:711908).Applicant
• Serebryakov et al., “Synthesis of 3-formyl-2-caproyl-1-cyclopentanol from 2-cyclopentenone”, Izv. Akad. Nauk SSSR, Ser. Khim vol. 8, 1978 pp. 1904-1906. (CAS 1978:597012).Applicant
• Sugie et al., “Synthesis of carbocyclic analogs of captopril (SQ-14225)” Chem. Pharm. Bull. vol. 27, No. 9, 1979 pp. 1708-1709 (CAS 1980:41393).Applicant
• Groves, John Kington, “Pyrrole chemistry. XV. Chemistry of some 3,4-disubstituted pyrroles” Can. J. Chem. vol. 51, No. 7 pp. 1089-1098. (CAS 1973:405203).Applicant
• Chemical Abstracts Service Accession No. 1999:388188, Document No. 131:44836.Applicant
• Chemical Abstracts Service Accession No. 1999:296090, Document No. 131:45075.Applicant
• Chemical Abstracts Service Accession No. 1997:711908, Document No. 128:22643.Applicant
• Chemical Abstracts Service Accession No. 1981:406626, Document No. 95:6626.Applicant
• Chemical Abstracts Service Accession No. 1980:585834, Document No. 93:185834.Applicant
• Chemical Abstracts Service Accession No. 1980:41393, Document No. 92:41393.Applicant
• Chemical Abstracts Service Accession No. 1979:610910, Document No. 91:210910.Applicant
• Chemical Abstracts Service Accession No. 1978:597012, Document No. 89:197102.Applicant
• Chemical Abstracts Service Accession No. 1973:405203, Document No. 79:5203.Applicant
• Printout for Konobevtsev et al. Stomatologiya, 61:7-9, 1982.Applicant
• Printout for Nishizawa et al., J. Antibiot, 41: 1629-43, 1988.Applicant
• Printout for Fukazawa et al. EP 333522, Sep. 1989.Applicant
• CAS Printout for Morita et al. JP 04009367, Jan. 1992.Applicant
• CAS Printout Holt et al. Bioorg Med. Chem. Lett., 4:315-20, 1994.Applicant
• CAS Printout for Steiner et al. Proc. Natl. Acad. Sci., 94 2019:2024, 1997.Applicant
• CAS Printout for Armistead et al. US 5654332, Aug. 1997.Applicant
• CAS Printout for Ognyanov et al. WO 9745115, Dec. 1997.Applicant
• CAS Printout for Armistead et al. US 5723459, Mar. 1998.Applicant
• CAS Printout for Lamb et al. J. Med. Chem., 41:3928-3939, 1998.Examiner